← LeonaBio, Inc. (LONA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
LeonaBio, Inc. (LONA)
Biological Products, (No Diagnostic Substances) · market cap $56M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-04-15 (est.)
Phase 3
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
LeonaBio (LONA) is a ~$45M market-cap biologics company (~9.4M shares at ~$4.76) whose data lists a broad, multi-indication pipeline led by an IL-23 therapy in Phase 3 for Crohn's disease. It has $32.3M of cash and a stated 9-month runway. The nearest high-importance event on our calendar is an estimated 2027-04-15 Phase 3 readout for lasofoxifene plus abemaciclib in metastatic breast cancer.
The catalyst path
- 2027-04-15 (est.)Phase 3 · Lasofoxifene in combination with abemaciclibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ATH-1017 | Phase 3 | Alzheimer Disease |
| IL-23 Therapy | Phase 3 | Crohn's Disease |
| Anti-Thymocyte Globulin (ATG) | Phase 2 | Diabetes Mellitus, Type 1 |
| Amitriptyline | Phase 2 | Quiescent Crohn's Disease (CD) |
| Lasofoxifene in combination with abemaciclib | Phase 3 | Metastatic Breast Cancer |
| REMD-477 | Phase 2 | Type 1 Diabetes |
| Pegylated GCSF | Phase 2 | Diabetes Mellitus, Type 1 |
| Granulocyte colony stimulating factor (GCSF) | Phase 2 | Diabetes Mellitus, Type 1 |
Price & technical context
3-month
-41.5%
6-month
-51.5%
12-month
+9.3%
52-wk range
$2.87–$11.68
vs 50-day MA
-22.1%
vs 200-day MA
-39.0%
Realized vol
114.7%
Max drawdown
-75.4%
Daily closes through 2026-11-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LONA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.